Neurocrine Biosciences, Inc. NBIX announced today that it has initiated a Phase IIb clinical trial (Kinect
Study) of its proprietary Vesicular Mono-Amine Transporter 2 compound,
NBI-98854. The design of this twelve-week Phase IIb study is a randomized,
parallel, double-blind, placebo-controlled, trial of 120 subjects with
moderate to severe tardive dyskinesia and underlying schizophrenia or
schizoaffective disorder. Topline data is expected in the second quarter of
2013.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in